Section: Computational Biology

In Silico Design of Peptide-Based Viral Entry Inhibitors Targeting Class I Fusion Proteins

Introduction

Class I fusion proteins are a structurally conserved group of viral glycoproteins that mediate the entry of numerous enveloped viruses into host cells. These proteins are characterized by a trimeric, rod-shaped ectodomain that undergoes a dramatic conformational rearrangement from a metastable pre-fusion state to a stable post-fusion six-helix bundle (6HB) [1]. This refolding process is essential for the apposition and fusion of the viral and cellular membranes. The 6HB is formed by the antiparallel association of three C-terminal heptad repeat (HR2) helices packing into hydrophobic grooves on a central trimeric coiled-coil of N-terminal heptad repeat (HR1) helices [1, 2]. This structural mechanism is shared by many important veterinary pathogens, including avian influenza virus (AIV), Newcastle disease virus (NDV), porcine reproductive and respiratory syndrome virus (PRRSV), and several paramyxoviruses and coronaviruses [2, 3].

The critical role of the HR1-HR2 interaction in membrane fusion makes it an attractive target for antiviral intervention. Peptides derived from the HR2 region (C-peptides) can bind to the exposed HR1 trimer during the intermediate state of the fusion process, competitively inhibiting the formation of the native 6HB and thereby blocking viral entry [1, 3]. Similarly, HR1-derived peptides (N-peptides) can target the HR2 region, though they are generally less potent due to aggregation tendencies [2]. The in silico design of these peptide inhibitors leverages computational biophysics and structural bioinformatics to optimize binding affinity, stability, and pharmacokinetic properties.

This article provides a comprehensive technical review of the computational strategies used to design peptide-based entry inhibitors targeting class I fusion proteins, with a focus on veterinary applications. The discussion covers the biophysical basis of the HR1-HR2 interaction, computational modeling of the coiled-coil bundle, peptide stability optimization, and the integration of molecular dynamics and docking simulations.

Biophysical Basis of Class I Fusion Protein-Mediated Entry

Class I fusion proteins are synthesized as single-chain precursors (e.g., HA0 for influenza, F0 for paramyxoviruses) that require proteolytic cleavage into two disulfide-linked subunits: a receptor-binding subunit (HA1, G1, or S1) and a fusion subunit (HA2, F1, or S2) [1, 2]. The fusion subunit contains the heptad repeat regions. Upon receptor binding and endocytosis, the fusion protein undergoes a conformational change that exposes the fusion peptide, which inserts into the target membrane [3]. This intermediate state features the extended HR1 trimer, which is transiently accessible. The subsequent collapse of HR2 onto HR1 drives the formation of the 6HB, pulling the viral and cellular membranes together [1, 2].

The heptad repeat is a sequence motif of seven amino acids (positions a through g) where positions a and d are typically hydrophobic and form the core of the coiled-coil [3]. In the HR1 trimer, these hydrophobic residues create a series of grooves that accommodate the complementary hydrophobic residues of the HR2 helices. The specificity and affinity of this interaction are governed by electrostatic and van der Waals forces, as well as hydrogen bonding between the helices [2, 3].

Computational Modeling of the HR1-HR2 Coiled-Coil Bundle

The three-dimensional structure of the 6HB is the starting point for rational peptide inhibitor design. When an experimental structure (e.g., from X-ray crystallography or cryo-electron microscopy) is available, it can be used directly for docking studies. For viruses where the structure is unknown, homology modeling is employed using templates from related class I fusion proteins [1]. The accuracy of the model is critical, as small deviations in the helical register can dramatically affect predicted binding energies.

The coiled-coil geometry is defined by parameters such as the superhelical radius, pitch, and crossing angle. Computational tools such as CCBuilder and COILS can generate idealized coiled-coil models based on the heptad repeat sequence [2]. These models can then be refined using energy minimization and molecular dynamics simulations to relax steric clashes and optimize side-chain conformations [3].

Displaying the HR1-HR2 Interface in a 3D Viewer

For detailed structural analysis, the HR1-HR2 interface should be visualized in a molecular graphics environment. The following steps outline a typical workflow for examining the binding interface:

  1. Load the 6HB structure (experimental or modeled) into a viewer such as PyMOL or UCSF Chimera.
  2. Select the HR1 trimer (chains A, B, C) and display it as a cartoon or ribbon representation. Color each chain differently.
  3. Select the HR2 helices (chains D, E, F) and display them as a surface or stick representation to highlight the binding interface.
  4. Identify the hydrophobic core residues at positions a and d of the HR1 heptad repeats. These residues form the grooves that accommodate the HR2 side chains.
  5. Map the electrostatic potential onto the HR1 surface to identify charged patches that may contribute to binding specificity.
  6. Measure the distance between key interacting residues (e.g., the center of mass of a hydrophobic HR2 side chain and the corresponding groove on HR1) to validate the docking pose.

This visual analysis informs the selection of peptide sequences for inhibitor design. The goal is to design a peptide that mimics the HR2 helix and binds with high affinity to the exposed HR1 trimer.

In Silico Design of Peptide Inhibitors

The design process involves several computational stages: sequence selection, structural modeling, binding affinity prediction, and stability optimization.

Sequence Selection and Peptide Length

The natural HR2 sequence is the primary template for C-peptide inhibitors. However, the full-length HR2 is often too long for practical synthesis and may have poor solubility. Computational methods are used to identify the minimal binding motif, typically a 28- to 40-residue peptide that covers the region with the highest binding affinity for HR1 [1, 3]. Sequence alignment of HR2 regions from different viral strains can identify conserved residues that are critical for binding, which should be retained in the inhibitor [2].

Binding Affinity Prediction

Molecular docking and free energy calculations are used to predict the binding affinity of candidate peptides to the HR1 trimer. Rigid-body docking (e.g., using ZDOCK or ClusPro) can generate initial poses, which are then refined using flexible docking or molecular dynamics simulations [1]. The binding free energy is estimated using methods such as molecular mechanics generalized Born surface area (MM-GBSA) or molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) [2, 3]. These calculations account for van der Waals interactions, electrostatic contributions, and solvation effects.

A high binding affinity (low dissociation constant, Kd) is necessary for effective inhibition. The computational predictions are used to rank candidate peptides and select the most promising ones for experimental validation.

Peptide Stability Optimization

Peptides in solution are prone to proteolytic degradation and conformational flexibility, which can reduce their in vivo efficacy. In silico optimization strategies aim to improve stability without compromising binding affinity.

Stapled Peptides: Hydrocarbon stapling involves the introduction of a covalent cross-link between two non-natural amino acids at positions i and i+4 or i+7 on the same helix [1]. This staple stabilizes the alpha-helical conformation, which is the active binding form. Computational tools can predict the optimal staple location by analyzing the helical propensity and the solvent accessibility of the side chains [2].

D-Amino Acid Substitution: Replacing L-amino acids with D-amino acids can increase resistance to proteases. However, this substitution can disrupt the helical structure. Computational modeling is used to identify positions where D-amino acid substitution is tolerated without significant loss of binding affinity [3].

PEGylation and Conjugation: The attachment of polyethylene glycol (PEG) chains or other moieties can improve solubility and half-life. In silico prediction of the effect of PEGylation on the peptide structure and binding is challenging but can be approximated using coarse-grained models [1].

Salt Bridge Engineering: The introduction of charged residues that form stabilizing salt bridges on the peptide surface can enhance helical stability. Computational mutagenesis scans can identify beneficial mutations that improve the free energy of folding [2].

Workflow for In Silico Inhibitor Design

The following Mermaid diagram illustrates a typical computational workflow for designing peptide-based entry inhibitors.

graph TD
    A[Viral Fusion Protein Sequence], > B[Identify HR1 and HR2 Regions]
    B, > C[Model 6HB Structure (Homology or Template)]
    C, > D[Analyze HR1-HR2 Interface]
    D, > E[Select HR2-Derived Peptide Sequence]
    E, > F[Generate Peptide 3D Model]
    F, > G[Dock Peptide to HR1 Trimer]
    G, > H[Calculate Binding Free Energy (MM-GBSA)]
    H, > I{Acceptable Affinity?}
    I, Yes, > J[Optimize Peptide Stability]
    I, No, > E
    J, > K[Stapling / D-Amino Acid / Salt Bridge Scan]
    K, > L[Re-Dock and Re-Calculate Affinity]
    L, > M{Improved Stability?}
    M, Yes, > N[Final Candidate Peptide]
    M, No, > J
    N, > O[In Vitro Validation]

Computational Tools and Algorithms

Several computational tools are commonly employed in this design pipeline. The table below summarizes key software and their primary functions.

| Tool/Algorithm | Function | Application in Peptide Design | | :-, | :-, | :-, | | BLAST / Clustal Omega | Sequence alignment and homology search | Identification of HR1/HR2 regions and conserved motifs [1] | | MODELLER / SWISS-MODEL | Homology modeling | Construction of 6HB structure from template [2] | | CCBuilder | Coiled-coil modeling | Generation of idealized HR1 trimer [3] | | PyMOL / UCSF Chimera | Molecular visualization | Analysis of binding interface and electrostatic surfaces [1] | | ZDOCK / ClusPro | Rigid-body protein-protein docking | Initial docking of peptide to HR1 trimer [2] | | GROMACS / AMBER | Molecular dynamics simulation | Refinement of docking poses and free energy calculation [3] | | MM-GBSA / MM-PBSA | Binding free energy calculation | Ranking of candidate peptides [1, 2] | | FoldX / Rosetta | Computational mutagenesis | Prediction of stability effects of mutations [3] |

Challenges and Considerations

Several challenges complicate the in silico design of peptide inhibitors. The dynamic nature of the fusion protein intermediate state means that the HR1 trimer may not be fully accessible or may adopt a conformation different from the final 6HB structure [1]. Computational models must account for this flexibility, often through ensemble docking or enhanced sampling molecular dynamics [2].

Peptide aggregation, particularly for N-peptides, is a major obstacle. The hydrophobic nature of the heptad repeat can cause self-association, reducing the effective concentration of the inhibitor [3]. Computational prediction of aggregation propensity (e.g., using TANGO or AGGRESCAN) is an important step in the design process [1].

Resistance mutations can arise in the HR1 region that reduce peptide binding affinity. In silico mutagenesis scans can identify potential escape mutations and guide the design of broad-spectrum inhibitors that target conserved residues [2].

Veterinary Applications

The principles described above have been applied to several veterinary pathogens. For avian influenza virus (AIV), C-peptides derived from the HA2 subunit have been shown to inhibit viral entry in vitro [1]. Similarly, for Newcastle disease virus (NDV), peptides targeting the F protein HR1 region have demonstrated antiviral activity [2]. The design of inhibitors for porcine reproductive and respiratory syndrome virus (PRRSV) and other arteriviruses, which also utilize class I fusion mechanisms, is an active area of research [3].

The computational workflow is also relevant to the design of inhibitors against coronaviruses of veterinary importance, such as feline infectious peritonitis virus (FIPV) and bovine coronavirus (BCoV). The spike (S) protein of these viruses contains HR1 and HR2 regions that form a 6HB, and peptide inhibitors targeting this interface have been explored [1, 2].

Conclusion

In silico design of peptide-based viral entry inhibitors targeting class I fusion proteins is a powerful approach that integrates structural biology, computational chemistry, and bioinformatics. By modeling the HR1-HR2 coiled-coil bundle and predicting binding affinities, researchers can rationally design peptides that block the critical membrane fusion step. Stability optimizations, including hydrocarbon stapling and D-amino acid substitution, enhance the therapeutic potential of these inhibitors. While challenges remain, particularly regarding the dynamic nature of the fusion intermediate and the potential for resistance, computational methods continue to advance and offer a promising pathway for developing antiviral agents for veterinary medicine.

References

[1] Eckert, D. M., & Kim, P. S. (2001). Mechanisms of viral membrane fusion and its inhibition. Annual Review of Biochemistry, 70, 777-810.

[2] Harrison, S. C. (2008). Viral membrane fusion. Nature Structural & Molecular Biology, 15(7), 690-698.

[3] Skehel, J. J., & Wiley, D. C. (2000). Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Review of Biochemistry, 69, 531-569. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.